The landscape of oncology is currently undergoing a paradigm shift as pharmaceutical giants Merck & Co. and biotechnology innovator Moderna…
Read More
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
The American Association of Pharmaceutical Scientists (AAPS) has unveiled a transformative agenda for its 2026 PharmSci 360 conference, slated for…
Read More
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The global response to the COVID-19 pandemic, characterized by mass vaccination campaigns and widespread viral exposure, has inadvertently created a…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
In a decisive regulatory move aimed at curbing the proliferation of high-potency, synthetic psychoactive substances, the U.S. Drug Enforcement Administration…
Read More
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
Chemotherapy-Induced Peripheral Neuropathy (CIPN) has long stood as one of the most debilitating side effects of cancer treatment, often forcing…
Read More
Pharma commercial vendor selection still runs on word of mouth and a Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the complex journey from clinical trial success to market entry, the final phase—commercialization—often represents the most…
Read More
Alphabet and Meta now spend nearly as much on R&D as pharma’s 10 largest drugmakers
The landscape of global research and development is undergoing a tectonic shift as the lines between Silicon Valley and the…
Read More
A plate of spaghetti: Talus Bio boasts 5,000-fold faster drug screening by skipping protein folding
The landscape of modern pharmaceutical research has been fundamentally altered by the advent of protein structure prediction tools, most notably…
Read More
Pharma tariffs reach smaller drugmakers as industry warns of R&D pressure
The landscape of the American pharmaceutical industry underwent a significant structural shift on September 29, 2026, as the federal government…
Read More
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
The pharmaceutical landscape is currently undergoing a rapid transformation, characterized by the integration of artificial intelligence in drug discovery, the…
Read More
